SimpleFunctions
Winner-take-all · 5 outcomes5 contractsKalshirefreshed 2 min agoCloses Jan 1, 2027 · 237d

Will the CDC end its recommendation for the Rotavirus vaccine

Leader sits at 16% across 5 bound outcomes, runner-up at 10%. This is a winner-take-all market — the headline is the leader’s price, not an arithmetic mean.

Leader probability

16%

COVID-19

runner-up 10¢leader 16¢

Outcomes

5

winner-take-all

Runner-up

10¢

Influenza

Spread

6pp

contested

24h volume

$509

thin orderbook

Closes

Jan 1, 2027

237 days

Venue

Kalshi

5 bound

30-day trend

0%50%100%-30d-3w-2w-1wtodayCOVID-19: 12% (9 days, 7 points)COVID-19: 12% on 2026-05-06Influenza: 10% (9 days, 2 points)Influenza: 10% on 2026-04-14Hepatitis B: 10% (9 days, 3 points)Hepatitis B: 10% on 2026-04-26
COVID-1912¢Influenza10¢Hepatitis B10¢
Top 3 candidates by current price · 9d

Bracket family

How the bracket ladder is priced.

Each row is one outcome on the venue. Sorted by 24h volume — the heaviest book is at the top.

Analysis

This probability reflects market expectations that the CDC will discontinue its recommendation for rotavirus vaccination at some point in the future. Currently priced at 13%, the market assigns low odds to this outcome occurring. The rotavirus vaccine remains a cornerstone of the childhood immunization schedule in the United States, with strong clinical evidence supporting its safety and effectiveness in preventing severe gastroenteritis. Market participants likely weigh the vaccine's established track record against potential future developments: emerging epidemiological data suggesting reduced disease burden, safety signals from adverse event monitoring systems, policy shifts prioritizing resource allocation, or changes in disease prevalence patterns. The outcome depends on CDC advisory committee deliberations and formal recommendation updates, which occur periodically but without fixed schedules. Resolution requires an official CDC statement ending the rotavirus vaccine recommendation for routine childhood immunization.

  • Current rotavirus vaccine coverage remains high (>90% among U.S. children), with no recent safety alerts or efficacy concerns in CDC surveillance systems
  • CDC's routine immunization recommendations rarely get rescinded absent compelling evidence of diminished disease burden or serious adverse events
  • Any recommendation change would require peer-reviewed epidemiological data demonstrating rotavirus no longer poses a significant public health threat in the U.S.
  • International vaccine policy shifts or WHO guidance changes could indirectly influence CDC decision-making, though the U.S. tends to maintain independent assessment
  • The timeline for any potential review is undefined; CDC periodically reassesses vaccines through ACIP but has no announced schedule for rotavirus re-evaluation

Recently closed in general

These markets stopped trading. Last odds and any captured outcome are shown above — full settlement detail lives at the venue.

More like this

Adjacent prediction questions.

How we compute these odds

SimpleFunctions aggregates live prediction-market contracts from Kalshi and Polymarket. Each slug groups contracts that resolve on the same underlying event, identified by venue event_id.

For binary slugs, the headline probability is the liquidity-weighted mid-price across all bound contracts. For multi-outcome slugs (e.g. elections with 3+ candidates), the headline is the leader’s price; we never arithmetically average disjoint outcomes — that would produce a number with no real-world meaning.

Snapshots refresh every 5 minutes during market hours; daily aggregates are computed at 04:00 UTC. The 30-day sparkline is drawn from per-ticker daily means stored in market_indicator_daily; 24h delta and movement events are derived from the same source.

Last updated on this page: 2 min ago.